Skip to main content

Table 1 Demographic and treatment characteristics of the analyzed cohort

From: Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy

 

Median (range)

  

Age

 

73 (65–96)

 

Age-adjusted CCI

 

4 (2–9)

 
  

n

%

Gender

Male

48

76.2

 

Female

15

23.8

Smoking

Non-smoker

17

27.0

 

Smoker

42

66.7

 

Missing

4

6.3

ECOG

ECOG 0

31

49.2

 

ECOG 1

27

42.9

 

ECOG 2

5

7.9

Localization

Nasopharynx

3

4.8

 

Oropharynx

26

41.3

 

Hypopharynx

12

19.0

 

Oral cavity

7

11.1

 

Larynx

13

20.6

 

Multi-level

1

1.6

 

Parotid gland

1

1.6

UICC

I

6

9.5

 

II

2

3.2

 

III

5

7.9

 

IV

50

79.4

cT

cT1

7

11.1

 

cT2

10

15.9

 

cT3

16

25.4

 

cT4

30

47.6

cN

cN0

16

25.4

 

cN1

3

4.8

 

cN2a

1

1.6

 

cN2b

25

39.7

 

cN2c

15

23.8

 

cN3

3

4.8

cM

cM0

63

100.0

 

cM1

0

0.0

Grading

G1

2

3.2

 

G2

43

68.3

 

G3

18

28.6

HPV

HPV-negative

25

39.7

 

HPV-positive

13

20.6

 

Missing

25

39.7

  

Median (range)

 

Dose (EQD2)

 

69.4 Gy (40.0–70.0 Gy)

 
  

n

%

Radiotherapy completed

Not completed

11

17.5

 

Completed

52

82.5

Chemotherapy

No chemotherapy

19

30.2

 

Chemotherapy

44

69.8

  1. A positive smoking status was considered in case of ≥ 10 pack years. Staging was performed using the 7th edition of the TNM classification